open access

Vol 6, Supp. A (2010)
suplement
Published online: 2010-11-22
Get Citation

Liposomal doxorubicin (Myocet®) with cyclophosphamide for first-line therapy of metastatic breast cancer in patient previously treated with anthracyclines in the adjuwant setting

Magdalena Kustra, Elżbieta Nowara

open access

Vol 6, Supp. A (2010)
suplement
Published online: 2010-11-22

Abstract

The anthracycline doxorubicin is among the most active dugs in breast cancer and included in chemotherapy regimens for all stages of breast cancer treatment. However, re-treatment with doxorubicin in metastatic disease is limited by a cumulative dose-dependent cardiotoxicity. Liposomal doxorubicin (Myocet®) is less cadiotoxic than doxorubicin with proven efficacy in metastatic breast cancer. In this case report Myocet® in combination with cyclophosphamide was used for first-line therapy of metastatic breast cancer in patient after doxorubicin-containing therapy as adjuvant treatment.
Onkol. Prak. Klin. 2010; supl. A: A25–A27

Abstract

The anthracycline doxorubicin is among the most active dugs in breast cancer and included in chemotherapy regimens for all stages of breast cancer treatment. However, re-treatment with doxorubicin in metastatic disease is limited by a cumulative dose-dependent cardiotoxicity. Liposomal doxorubicin (Myocet®) is less cadiotoxic than doxorubicin with proven efficacy in metastatic breast cancer. In this case report Myocet® in combination with cyclophosphamide was used for first-line therapy of metastatic breast cancer in patient after doxorubicin-containing therapy as adjuvant treatment.
Onkol. Prak. Klin. 2010; supl. A: A25–A27
Get Citation

Keywords

metastatic breast cancer; anthracycline chemotherapy; liposomal doxorubicin; cardiotoxicity

About this article
Title

Liposomal doxorubicin (Myocet®) with cyclophosphamide for first-line therapy of metastatic breast cancer in patient previously treated with anthracyclines in the adjuwant setting

Journal

Oncology in Clinical Practice

Issue

Vol 6, Supp. A (2010)

Pages

25-27

Published online

2010-11-22

Keywords

metastatic breast cancer
anthracycline chemotherapy
liposomal doxorubicin
cardiotoxicity

Authors

Magdalena Kustra
Elżbieta Nowara

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl